Faron Pharmaceuticals Oy (LON:FARN) Trading Down 11.6% - Here's What Happened

Key Points

• Shares fell 11.6% on Wednesday, trading as low as GBX 46 and last at GBX 47.29 on volume of 264,198 shares (up 41% versus the 187,918 average), after a previous close of GBX 53.50.
• The stock trades far below its technicals — 50‑day MA GBX 125.07 and 200‑day MA GBX 164.88 — and has a market cap of £54.42 million with a negative P/E (−1.74), indicating the company is currently unprofitable.
• Insider activity: Director Jurriaan Dekkers sold 4,000 shares at GBX 182 on Jan 12 for £7,280; insiders own 3.94% of the company, underscoring that earlier insider sales occurred at much higher prices than today’s levels.

Faron Pharmaceuticals Oy (LON:FARN - )'s share price traded down 11.6% on Wednesday . The company traded as low as GBX 46 and last traded at GBX 47.29. 264,198 shares were traded during trading, an increase of 41% from the average session volume of 187,918 shares. The stock had previously closed at GBX 53.50.

Faron Pharmaceuticals Oy Stock Performance

The stock has a fifty day moving average of GBX 125.07 and a 200-day moving average of GBX 164.88. The company has a quick ratio of 1.09, a current ratio of 0.84 and a debt-to-equity ratio of -133.35. The stock has a market capitalization of £54.42 million, a PE ratio of -1.74 and a beta of 1.60.

Insider Activity at Faron Pharmaceuticals Oy

In other Faron Pharmaceuticals Oy news, insider Jurriaan Dekkers sold 4,000 shares of Faron Pharmaceuticals Oy stock in a transaction dated Monday, January 12th. The stock was sold at an average price of GBX 182, for a total transaction of £7,280. Insiders own 3.94% of the company's stock.

Faron Pharmaceuticals Oy Company Profile

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.